Monjuvi

(Tafasitamab)

Monjuvi

Drug updated on 11/15/2023

Dosage FormInjection (intravenous: 200 mg)
Drug ClassCD19-directed cytolytic antibodies
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).